Venetoclax to Augment Epigenetic Modification and Chemotherapy
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat
followed by standard chemotherapy to enhance treatment response in AML patients.